Skip to main content

Revlimid Disease Interactions

There are 3 disease interactions with Revlimid (lenalidomide).

Moderate

Lenalidomide (applies to Revlimid) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Lenalidomide is primarily excreted unchanged by the kidney. Adjustments to the starting dose are recommended in patients with moderate (CrCl 30-60 mL/min) or severe renal impairment (<30 mL/min), and in patients on dialysis.

Switch to professional interaction data

Moderate

Lenalidomide (applies to Revlimid) thromboembolic events

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: History - Thrombotic/Thromboembolic Disorder, Pulmonary Embolism

Venous thromboembolic events (deep venous thrombosis and pulmonary embolism) and arterial thromboses are increased in patients using lenalidomide. Patients with known risk factors such as prior thrombosis, may be at greater risk and actions should be taken to minimize all other modifiable risk factors (e.g., smoking, hyperlipidemia, hypertension).

Switch to professional interaction data

Moderate

Miscellaneous antineoplastics (applies to Revlimid) anemia

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Neutropenia, Thrombocytopenia

Some miscellaneous antineoplastics such as azacitidine and lenalidomide cause anemia, neutropenia, and thrombocytopenia. Patients with these preexisting conditions should be monitored carefully. Monitor complete blood counts frequently for response and/or toxicity, at a minimum, prior to each dosing cycle.

Switch to professional interaction data

Revlimid drug interactions

There are 269 drug interactions with Revlimid (lenalidomide).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer